

Commentary

T cells and post menopausal osteoporosis in murine models

Roberto Pacifici

Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA

Corresponding author: Roberto Pacifici, roberto.pacifici@emory.edu

Published: 5 March 2007

This article is online at <http://arthritis-research.com/content/9/2/102>

© 2007 BioMed Central Ltd

Arthritis Research & Therapy 2007, **9**:102 (doi:10.1186/ar2126)**Abstract**

Estrogen deficiency is one of the most frequent causes of osteoporosis in women and a possible cause of bone loss in men. But the mechanism involved remains largely unknown. Estrogen deficiency leads to an increase in the immune function, which culminates in an increased production of tumor necrosis factor (TNF) by activated T cells. TNF increases osteoclast formation and bone resorption both directly and by augmenting the sensitivity of maturing osteoclasts to the essential osteoclastogenic factor RANKL (the RANK ligand). Increased T cell production of TNF is induced by estrogen deficiency via a complex mechanism mediated by antigen presenting cells and the cytokines IFN γ , IL-7 and transforming growth factor- β . The experimental evidence that suggests that estrogen prevents bone loss by regulating T cell function and the interactions between immune cells and bone is reviewed here.

Estrogen deficiency is the most frequent cause of bone loss in humans. Bone loss results both from decreased ovarian production of sex steroids and the increase in follicle stimulating hormone (FSH) production induced by estrogen deficiency. FSH is now known to directly stimulate the production of tumor necrosis factor (TNF), a potent osteoclastogenic cytokine from bone marrow granulocytes and macrophages [1,2]. While FSH is likely to play a relevant role in the mechanism by which natural and surgical menopause lead to bone loss, this article will focus on the direct (FSH independent) mechanisms by which estrogen deficiency causes bone loss.

Estrogen deficiency is experimentally induced by ovariectomy (ovx). The main effect of ovx is a marked stimulation of bone resorption, which is caused primarily by increased osteoclast (OC) formation, but estrogen deficiency also increases OC lifespan due to reduced apoptosis [3]. The net bone loss caused by increased OC number and life span is limited in part by a compensatory augmentation of bone formation within each remodeling unit. This event is a consequence of

stimulated osteoblastogenesis fueled by an expansion of the pool of early mesenchymal progenitors, and by increased commitment of such pluripotent precursors toward the osteoblastic lineage [4]. In spite of stimulated osteoblastogenesis, the net increase in bone formation is inadequate to compensate for enhanced bone resorption because of an augmentation in osteoblast (OB) apoptosis, a phenomenon also induced by estrogen deficiency [5]. An additional event triggered by estrogen withdrawal that limits the magnitude of the compensatory elevation in bone formation is the increased production of inflammatory cytokines such as IL-7 and TNF, which limit the functional activity of mature OBs [6,7]. Increased bone resorption, trabecular thinning and perforation, and a loss of connection between the remaining trabeculae are the dominant features of the initial phase of rapid bone loss that follows the onset of estrogen deficiency [8]. This acute phase is followed by a long-lasting period of slower bone loss where the dominant microarchitectural change is trabecular thinning. This phase is due, in part, to impaired osteoblastic activity secondary to increased OB apoptosis [9].

OC formation is induced by the cytokines 'receptor activator of NF- κ B ligand' (RANKL) and macrophage colony stimulating factor (M-CSF). These factors are produced primarily by bone marrow (BM) stromal cells and OBs [10], and activated T cells [11]. RANKL binds to RANK, a receptor expressed on OCs and OC precursors, and to osteoprotegerin, a soluble decoy receptor produced by numerous hematopoietic cells. Thus, osteoprotegerin, by sequestering RANKL and preventing its binding to RANK, functions as an anti-osteoclastogenic cytokine. M-CSF induces the proliferation of OC precursors, the differentiation of more mature OCs, and increases the survival of mature OCs. RANKL promotes the differentiation of OC precursors from an early stage of maturation into fully mature multinucleated OCs and activates mature OCs.

BM = bone marrow; ERE = estrogen responsive element; FSH = follicle stimulating hormone; IFN = interferon; IL = interleukin; M-CSF = macrophage colony stimulating factor; OB = osteoblast; OC = osteoclast; ovx = ovariectomy; RANK = receptor activator of NF- κ B; RANKL = RANKL ligand; TGF = transforming growth factor; TNF, tumor necrosis factor.

Additional cytokines, either produced by or regulating T cells, are responsible for the upregulation of OC formation observed in a variety of conditions, such as inflammation, and estrogen deficiency. One such factor is TNF, a cytokine that enhances OC formation by upregulating the stromal cell production of RANKL and M-CSF [12] and by augmenting the responsiveness of OC precursors to RANKL [13]. Furthermore, TNF stimulates OC activity and inhibits osteoblastogenesis [12], thus further driving an imbalance between bone formation and bone resorption. The relevance of TNF has been demonstrated in multiple animal models. For example, ovx fails to induce bone loss in mice lacking TNF or its type 1 receptor [14]. Likewise, transgenic mice insensitive to TNF due to the overexpression of a soluble TNF receptor [15], and mice treated with the TNF inhibitor TNF binding protein [16] are protected from ovx-induced bone loss.

The presence of increased levels of TNF in the BM of ovx animals and in the conditioned media of peripheral blood cells of postmenopausal women is well documented [17]. However, the cells responsible for this phenomenon had not been conclusively identified. Recent studies on highly purified BM cells have revealed that ovx increases the production of TNF by T cells, but not by monocytes [13], and that earlier identification of TNF production by monocytes was likely due to T cell contamination of monocytes purified by adherence. Thus, the ovx-induced increase in TNF levels is likely to be due to T cell TNF production. Attesting to the relevance of T cells in estrogen deficiency induced bone loss *in vivo*, measurements of trabecular bone by peripheral quantitative computed tomography and μ -computed tomography revealed that athymic T cell deficient nude mice are completely protected against the trabecular bone loss induced by ovx [13,14,18]. T cells are key inducers of bone-wasting because ovx increases T cell TNF production to a level sufficient to augment RANKL-induced osteoclastogenesis [13]. T cell produced TNF may further augment bone loss by stimulating T cell RANKL production. The specific relevance of T cell TNF production *in vivo* was demonstrated by the finding that while reconstitution of nude recipient mice with T cells from wild-type mice restores the capacity of ovx to induce bone loss, reconstitution with T cells from TNF deficient mice does not [14].

Ovx upregulates T cell TNF production by increasing the number of TNF producing T cells without altering the amount of TNF produced by each T cell [14]. Ovx causes an expansion of the T cell pool in the BM by increasing T cell activation, a phenomenon that results in increased T cell proliferation and life span. Ovx increases T cell activation by enhancing antigen presentation by BM macrophages [19] and dendritic cells. This phenomenon is a result of the ability of estrogen deficiency to upregulate the expression of major histocompatibility complex II and the costimulatory molecule CD80. Although the mechanism of T cell activation elicited by estrogen deficiency is similar to that triggered by infections,

the intensity of the events that follow estrogen withdrawal is significantly less severe and this process should be envisioned as a partial increase in T cell autoreactivity to self-peptides resulting in a modest expansion in the pool of effector CD4⁺ cells.

The physiological inducer of major histocompatibility complex II expression is IFN γ , an inflammatory cytokine produced by helper T cells. Ovx increases T cell production of IFN γ through complex mechanisms that remain largely unknown. The relevance of IFN γ is shown by the failure of mice lacking the IFN γ receptor (IFN γ R^{-/-}) and IFN γ (IFN γ ^{-/-} mice) to sustain bone loss in response to ovx [19,20].

A mechanism by which estrogen deficiency upregulates the production of IFN γ is through repression of transforming growth factor (TGF) β production [18]. The production of TGF β by bone and BM cells is directly stimulated by estrogen through binding of the activated estrogen receptor on an estrogen responsive element (ERE) element on the TGF β promoter [21]. Thus, estrogen withdrawal leads to increased production of TGF β in the BM. TGF β receptors are expressed in T cells and TGF β signaling in T cells leads to powerful repression of T cell activation and of their production of IFN γ . Thus, TGF β blocks T cell activation both directly and by decreasing antigen presentation via diminished production of IFN γ .

Studies with a transgenic mouse that expresses a dominant negative form of the TGF β receptor in T cells have allowed the significance of the repressive effects of this cytokine on T cell function in the bone loss associated with estrogen deficiency to be established [18]. This strain, known as CD4dnTGF β RII, is severely osteopenic due to increased bone resorption. More importantly, mice with T cell-specific blockade of TGF β signaling are completely insensitive to the bone sparing effect of estrogen [18]. This phenotype results from a failure of estrogen to repress IFN γ production which, in turn, leads to increased T cell activation and T cell TNF production.

As a proof of principle, a somatic gene therapy approach was used to induce the overexpression of TGF β 1 in ovx mice. These experiments confirmed that elevation of the systemic levels of TGF β prevents the bone loss and the increase in bone turnover induced by ovx [18].

Another mechanism by which estrogen regulates IFN γ production is through IL-7, a potent lymphopoietic cytokine and inducer of bone destruction *in vivo* [22]. IL-7 is produced primarily by bone marrow stromal cells and OBs, but the mechanism by which ovx increases IL-7 production and the exact source of this cytokine remain to be determined. The BM levels of IL-7 are significantly elevated following ovx [6,23,24], and *in vivo* IL-7 blockade, using neutralizing antibodies, is effective in preventing ovx induced bone destruction [6] by suppressing T cell expansion and T cell IFN γ

- menopausal) osteoporosis: quantitative assessment of rates of formation, resorption, bone loss at tissue and cellular levels. *J Bone Miner Res* 1990, **5**:311-319.
9. Riggs BL, Parfitt AM: **Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.** *J Bone Miner Res* 2005, **20**:177-184.
 10. Khosla S: **Minireview: the OPG/RANKL/RANK system.** *Endocrinology* 2001, **142**:5050-5055.
 11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, *et al.*: **OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.** *Nature* 1999, **397**:315-323.
 12. Nanes MS: **Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology.** *Gene* 2003, **321**:1-15.
 13. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R: **Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha.** *J Clin Invest* 2000, **106**:1229-1237.
 14. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G, Pacifici R: **Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo.** *Proc Natl Acad Sci USA* 2001, **98**:13960-13965.
 15. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia I: **Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.** *J Clin Invest* 1997, **99**:1699-1703.
 16. Kimble R, Bain S, Pacifici R: **The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.** *J Bone Miner Res* 1997, **12**:935-941.
 17. Weitzmann MN, Pacifici R: **Estrogen deficiency and bone loss: an inflammatory tale.** *J Clin Invest* 2006, **116**:1186-1194.
 18. Gao Y, Qian WP, Dark K, Toraldo G, Lin AS, Guldborg RE, Flavell RA, Weitzmann MN, Pacifici R: **Estrogen prevents bone loss through transforming growth factor beta signaling in T cells.** *Proc Natl Acad Sci USA* 2004, **101**:16618-16623.
 19. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O, Pacifici R: **Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator.** *Proc Natl Acad Sci USA* 2003, **100**:10405-10410.
 20. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X, Weitzmann MN, Pacifici R: **IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation.** *J Clin Invest* 2007, **117**:122-132.
 21. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: **Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifene.** *Science* 1996, **273**:1222-1225.
 22. Miyaura C, Onoe Y, Inada M, Maki K, Ikuta K, Ito M, Suda T: **Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency.** *Proc Natl Acad Sci USA* 1997, **19**:9360-9365.
 23. Ryan MR, Shepherd R, Leavey JK, Gao Y, Grassi F, Schnell FJ, Qian WP, Kersh GJ, Weitzmann MN, Pacifici R: **An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency.** *Proc Natl Acad Sci USA* 2005, **102**:16735-16740.
 24. Lindberg MK, Svensson J, Venken K, Chavoshi T, Andersson N, Moverare Skrtic S, Isaksson O, Vanderschueren D, Carlsten H, Ohlsson C: **Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss.** *Bone* 2006, **38**:85-92.
 25. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, *et al.*: **IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.** *J Clin Invest* 2002, **109**:931-937.
 26. Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ, McBride WH: **Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7.** *J Natl Cancer Inst* 1995, **87**:593-597.
 27. Haynes BF, Sempowski GD, Wells AF, Hale LP: **The human thymus during aging.** *Immunol Res* 2000, **22**:253-261.
 28. Steinmann GG, Klaus B, Muller-Hermelink HK: **The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study.** *Scand J Immunol* 1985, **22**:563-575.
 29. Hakim FT, Memon SA, Cepeda R, Jones EC, Chow CK, Kasten-Sportes C, Odom J, Vance BA, Christensen BL, Mackall CL, *et al.*: **Age-dependent incidence, time course, and consequences of thymic renewal in adults.** *J Clin Invest* 2005, **115**:930-939.
 30. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, *et al.*: **Augmentation of T cell levels and responses induced by androgen deprivation.** *J Immunol* 2004, **173**:6098-6108.
 31. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, Blazar BR, Millar JL, Malin MA, Chidgey AP, *et al.*: **Activation of thymic regeneration in mice and humans following androgen blockade.** *J Immunol* 2005, **175**:2741-2753.